Showing 2231-2240 of 7330 results for "".
Physician Spotlight: Bruce E. Strober MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-bruce-e-strober-md-phd/23010/Physician Spotlight
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight/22078/Dealing with Prescription Prior Authorization in Dermatology
https://practicaldermatology.com/topics/practice-management/dealing-with-prescription-prior-authorization-in-dermatology/22079/Complaints and concerns abound, but remedies are slow in coming.A First Look at Rotational Fractional Resection
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-first-look-at-rotational-fractional-resection/20383/A new technology offers a fresh approach to treatment of submental contouring.Therapeutics Update: New products and pharmacologic developments
https://practicaldermatology.com/columns/new-products/therapeutics-update-new-products-and-pharmacologic-developments/20390/What's Your Priority?
https://practicaldermatology.com/topics/practice-management/whats-your-priority/20309/Prioritization skills are essential, because everything will end up on your plate.Repairing the Ellipse; Resident Salary Update
https://practicaldermatology.com/youngmd-connect/resident-resource-center/repairing-the-ellipse-resident-salary-update/20414/Subcision Plus Sublative Technologies to Treat Acne Scars
https://practicaldermatology.com/topics/general-topics/subcision-plus-sublative-technologies-to-treat-acne-scars/20462/Combining something old and something new to create something skintastic.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20454/Skin Cancer Awareness, Epiduo Data, Impoyz Launch
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-skin-cancer-awareness-epiduo-data-impoyz-launch/18307/Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations